Author | Thomas E. Stinchcombe, MD | OncLive

Author | Thomas E. Stinchcombe, MD

Articles

Dr. Stinchcombe on the ALTA-1L Trial in ALK+ NSCLC

January 31, 2020

Video

Thomas E. Stinchcombe, MD, discusses the results of the randomized phase III ALTA-1L trial in ALK-positive non–small cell lung cancer.

Dr. Stinchcombe on Molecular Testing in ALK+ NSCLC

January 22, 2020

Video

Thomas E. Stinchcombe, MD, discusses the importance of molecular testing in ALK-positive non–small cell lung cancer.

Dr. Stinchcombe on Remaining Challenges in ALK+ NSCLC

January 02, 2020

Video

Thomas E. Stinchcombe, MD, discusses remaining challenges in ALK-positive non­–small cell lung cancer.

Dr. Stinchcombe Discusses Differences in Toxicity Profiles Among ALK Inhibitors in NSCLC

July 02, 2019

Video

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the differences in toxicity profiles between brigatinib (Alunbrig) and alectinib (Alecensa) in ALK-positive non–small cell lung cancer (NSCLC).

x